Efficacy, Safety, and Cost-Effectiveness of the Infliximab Biosimilar GP-1111 in Patients with Inflammatory Bowel Disease Who Underwent a Nonmedical Switch A Prospective Cohort Study /

Hasonló tételek

• Switching from infliximab to biosimilar in inflammatory bowel disease
  Szerző: Milassin Ágnes, et al.
  Megjelent: (2019)
• Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease results of a multicenter survey /
  Szerző: Sarlós Patrícia, et al.
  Megjelent: (2023)
• A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease
  Szerző: Farkas Klaudia, et al.
  Megjelent: (2018)
• Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases a prospective; multicentre; nationwide cohort /
  Szerző: Gecse Krisztina Barbara, et al.
  Megjelent: (2016)
• Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases results from Central European nationwide cohort /
  Szerző: Bálint Anita, et al.
  Megjelent: (2017)